Dynavax Technologies (NASDAQ:DVAX) Posts Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Dynavax Technologies (NASDAQ:DVAX) reported quarterly earnings of $0.21 EPS, exceeding expectations by $0.07. The company generated revenue of $94.88 million, surpassing the consensus estimate of $94.00 million. Despite a negative net margin of 16.67%, it achieved a positive return on equity of 5.10%. The stock traded at $10.30, with a market cap of $1.21 billion. Analysts have mixed ratings, with three recommending a buy and two a sell, while the average target price is $24.33.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.14 by $0.07, Zacks reports. The firm had revenue of $94.88 million for the quarter, compared to the consensus estimate of $94.00 million. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%.

Get Dynavax Technologies alerts:

Dynavax Technologies Stock Performance

NASDAQ DVAX traded up $0.25 during trading hours on Wednesday, hitting $10.30. 2,378,061 shares of the stock were exchanged, compared to its average volume of 1,977,836. Dynavax Technologies has a 12-month low of $9.20 and a 12-month high of $14.63. The stock has a 50-day moving average of $9.99 and a 200 day moving average of $10.28. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -22.39 and a beta of 1.09. The company has a quick ratio of 6.01, a current ratio of 6.65 and a debt-to-equity ratio of 0.45.

Insider Transactions at Dynavax Technologies

In other Dynavax Technologies news, Director Scott Dunseth Myers bought 3,800 shares of the business's stock in a transaction dated Friday, August 22nd. The stock was acquired at an average cost of $10.82 per share, with a total value of $41,116.00. Following the purchase, the director owned 35,004 shares in the company, valued at approximately $378,743.28. This represents a 12.18% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 2.98% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of DVAX. Osaic Holdings Inc. lifted its holdings in Dynavax Technologies by 15.1% in the second quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company's stock valued at $93,000 after acquiring an additional 1,226 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Dynavax Technologies by 1.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 86,421 shares of the biopharmaceutical company's stock valued at $1,126,000 after purchasing an additional 1,625 shares in the last quarter. E Fund Management Co. Ltd. increased its holdings in shares of Dynavax Technologies by 17.9% in the 2nd quarter. E Fund Management Co. Ltd. now owns 18,113 shares of the biopharmaceutical company's stock valued at $180,000 after purchasing an additional 2,752 shares in the last quarter. Envestnet Asset Management Inc. lifted its stake in shares of Dynavax Technologies by 55.3% in the third quarter. Envestnet Asset Management Inc. now owns 20,888 shares of the biopharmaceutical company's stock valued at $207,000 after purchasing an additional 7,441 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in Dynavax Technologies by 319.8% during the second quarter. Tower Research Capital LLC TRC now owns 16,239 shares of the biopharmaceutical company's stock worth $161,000 after buying an additional 12,371 shares in the last quarter. Institutional investors and hedge funds own 96.96% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on DVAX. Wall Street Zen raised shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. JMP Securities reaffirmed a "market outperform" rating and issued a $32.00 target price on shares of Dynavax Technologies in a report on Friday, August 22nd. Finally, Weiss Ratings reissued a "sell (d)" rating on shares of Dynavax Technologies in a report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Dynavax Technologies presently has an average rating of "Hold" and a consensus price target of $24.33.

Get Our Latest Report on DVAX

Dynavax Technologies Company Profile

(Get Free Report)

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

Should You Invest $1,000 in Dynavax Technologies Right Now?

Before you consider Dynavax Technologies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.

While Dynavax Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here